메뉴 건너뛰기




Volumn 6, Issue 294, 2013, Pages

Profiles of basal and stimulated receptor signaling networks predict drug response in breast cancer lines

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; A 6730; AFATINIB; BOSUTINIB; ERLOTINIB; GEFITINIB; GROWTH FACTOR RECEPTOR; GSK 1059615; GSK 1070916; GSK 2119563; GSK 2126458; GSK 461364; LAPATINIB; LIGAND; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NEU DIFFERENTIATION FACTOR; OXAMFLATIN; PANOBINOSTAT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; SELUMETINIB; TCS 2312; TEMSIROLIMUS; TRAMETINIB; TRASTUZUMAB; TRICIRIBINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

EID: 84885722700     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2004379     Document Type: Article
Times cited : (83)

References (64)
  • 3
    • 0032850677 scopus 로고    scopus 로고
    • Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
    • M. A. Cobleigh, C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrenbacher, J. M. Wolter, V. Paton, S. Shak, G. Lieberman, D. J. Slamon, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648 (1999).
    • (1999) J. Clin. Oncol. , vol.17 , pp. 2639-2648
    • Cobleigh, M.A.1    Vogel, C.L.2    Tripathy, D.3    Robert, N.J.4    Scholl, S.5    Fehrenbacher, L.6    Wolter, J.M.7    Paton, V.8    Shak, S.9    Lieberman, G.10    Slamon, D.J.11
  • 9
    • 84885706147 scopus 로고    scopus 로고
    • accessed 28 August 2013
    • National Cancer Institute, http://www.cancer.gov/ [accessed 28 August 2013].
  • 12
    • 77949903478 scopus 로고    scopus 로고
    • Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy
    • J. Baselga, K. A. Gelmon, S. Verma, A. Wardley, P. Conte, D. Miles, G. Bianchi, J. Cortes, V. A. McNally, G. A. Ross, P. Fumoleau, L. Gianni, Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 28, 1138-1144 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , pp. 1138-1144
    • Baselga, J.1    Gelmon, K.A.2    Verma, S.3    Wardley, A.4    Conte, P.5    Miles, D.6    Bianchi, G.7    Cortes, J.8    McNally, V.A.9    Ross, G.A.10    Fumoleau, P.11    Gianni, L.12
  • 14
    • 19344364880 scopus 로고    scopus 로고
    • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
    • Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
    • Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365, 1687-1717 (2005).
    • (2005) Lancet , vol.365 , pp. 1687-1717
  • 15
    • 33645459056 scopus 로고    scopus 로고
    • Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93
    • International Breast Cancer Study Group
    • International Breast Cancer Study Group, M. Colleoni, S. Gelber, A. Goldhirsch, S. Aebi, M. Castiglione-Gertsch, K. N. Price, A. S. Coates, R. D. Gelber, Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J. Clin. Oncol. 24, 1332-1341 (2006).
    • (2006) J. Clin. Oncol. , vol.24 , pp. 1332-1341
    • Colleoni, M.1    Gelber, S.2    Goldhirsch, A.3    Aebi, S.4    Castiglione-Gertsch, M.5    Price, K.N.6    Coates, A.S.7    Gelber, R.D.8
  • 22
    • 84877028141 scopus 로고    scopus 로고
    • Comprehensive molecular portraits of human breast tumours
    • The Cancer Genome Atlas Network
    • The Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
    • (2012) Nature , vol.490 , pp. 61-70
  • 24
    • 84873089796 scopus 로고    scopus 로고
    • Updates in the treatment of basal/triple-negative breast cancer
    • M. Shastry, D. A. Yardley, Updates in the treatment of basal/triple-negative breast cancer. Curr. Opin. Obstet. Gynecol. 25, 40-48 (2013).
    • (2013) Curr. Opin. Obstet. Gynecol. , vol.25 , pp. 40-48
    • Shastry, M.1    Yardley, D.A.2
  • 29
    • 84860851412 scopus 로고    scopus 로고
    • Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks
    • M. J. Lee, A. S. Ye, A. K. Gardino, A. M. Heijink, P. K. Sorger, G. MacBeath, M. B. Yaffe, Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780-794 (2012).
    • (2012) Cell , vol.149 , pp. 780-794
    • Lee, M.J.1    Ye, A.S.2    Gardino, A.K.3    Heijink, A.M.4    Sorger, P.K.5    MacBeath, G.6    Yaffe, M.B.7
  • 34
    • 0033304746 scopus 로고    scopus 로고
    • erbB-2 overexpression in human mammary epithelial cells confers growth factor independence
    • K. M. Ignatoski, A. J. Lapointe, E. H. Radany, S. P. Ethier, erbB-2 overexpression in human mammary epithelial cells confers growth factor independence. Endocrinology 140, 3615-3622 (1999).
    • (1999) Endocrinology , vol.140 , pp. 3615-3622
    • Ignatoski, K.M.1    Lapointe, A.J.2    Radany, E.H.3    Ethier, S.P.4
  • 35
    • 0031010495 scopus 로고    scopus 로고
    • Secondary dimerization between members of the epidermal growth factor receptor family
    • D. C. Gamett, G. Pearson, R. A. Cerione, I. Friedberg, Secondary dimerization between members of the epidermal growth factor receptor family. J. Biol. Chem. 272, 12052-12056 (1997).
    • (1997) J. Biol. Chem. , vol.272 , pp. 12052-12056
    • Gamett, D.C.1    Pearson, G.2    Cerione, R.A.3    Friedberg, I.4
  • 36
    • 28244432561 scopus 로고    scopus 로고
    • Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
    • R. Nahta, L. X. Yuan, B. Zhang, R. Kobayashi, F. J. Esteva, Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 65, 11118-11128 (2005).
    • (2005) Cancer Res. , vol.65 , pp. 11118-11128
    • Nahta, R.1    Yuan, L.X.2    Zhang, B.3    Kobayashi, R.4    Esteva, F.J.5
  • 41
    • 44449151030 scopus 로고    scopus 로고
    • Drug development of MET inhibitors: Targeting oncogene addiction and expedience
    • P. M. Comoglio, S. Giordano, L. Trusolino, Drug development of MET inhibitors: Targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 7, 504-516 (2008).
    • (2008) Nat. Rev. Drug Discov. , vol.7 , pp. 504-516
    • Comoglio, P.M.1    Giordano, S.2    Trusolino, L.3
  • 42
    • 84859415553 scopus 로고    scopus 로고
    • Molecular pathways: Fibroblast growth factor signaling: A new therapeutic opportunity in cancer
    • A. N. Brooks, E. Kilgour, P. D. Smith, Molecular pathways: Fibroblast growth factor signaling: A new therapeutic opportunity in cancer. Clin. Cancer Res. 18, 1855-1862 (2012).
    • (2012) Clin. Cancer Res. , vol.18 , pp. 1855-1862
    • Brooks, A.N.1    Kilgour, E.2    Smith, P.D.3
  • 43
    • 0037591513 scopus 로고    scopus 로고
    • Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients
    • T. Bachelot, I. Ray-Coquard, C. Menetrier-Caux, M. Rastkha, A. Duc, J. Y. Blay, Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br. J. Cancer 88, 1721-1726 (2003).
    • (2003) Br. J. Cancer , vol.88 , pp. 1721-1726
    • Bachelot, T.1    Ray-Coquard, I.2    Menetrier-Caux, C.3    Rastkha, M.4    Duc, A.5    Blay, J.Y.6
  • 45
    • 0033036097 scopus 로고    scopus 로고
    • Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma
    • G. J. Zhang, I. Adachi, Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 19, 1427-1432 (1999).
    • (1999) Anticancer Res. , vol.19 , pp. 1427-1432
    • Zhang, G.J.1    Adachi, I.2
  • 46
    • 40449113978 scopus 로고    scopus 로고
    • Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
    • D. L. Shattuck, J. K. Miller, K. L. Carraway III, C. Sweeney, Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 68, 1471-1477 (2008).
    • (2008) Cancer Res. , vol.68 , pp. 1471-1477
    • Shattuck, D.L.1    Miller, J.K.2    Carraway III, K.L.3    Sweeney, C.4
  • 47
    • 84885815639 scopus 로고    scopus 로고
    • ClinicalTrials.gov accessed 28 August 2013
    • ClinicalTrials.gov, http://clinicaltrials.gov [accessed 28 August 2013].
  • 48
    • 84875554160 scopus 로고    scopus 로고
    • Genomic determinants of PI3K pathway inhibitor response in cancer
    • B. Weigelt, J. Downward, Genomic determinants of PI3K pathway inhibitor response in cancer. Front. Oncol. 2, 109 (2012).
    • (2012) Front. Oncol. , vol.2 , pp. 109
    • Weigelt, B.1    Downward, J.2
  • 51
    • 63449138706 scopus 로고    scopus 로고
    • Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation
    • A. Roidl, H. J. Berger, S. Kumar, J. Bange, P. Knyazev, A. Ullrich, Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin. Cancer Res. 15, 2058-2066 (2009).
    • (2009) Clin. Cancer Res. , vol.15 , pp. 2058-2066
    • Roidl, A.1    Berger, H.J.2    Kumar, S.3    Bange, J.4    Knyazev, P.5    Ullrich, A.6
  • 60
    • 84885049277 scopus 로고    scopus 로고
    • Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110a inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers
    • 10.1158/0008-5472.CAN-13-1191
    • J. T. Garrett, C. R. Sutton, R. Kurupi, C. U. Bialucha, S. A. Ettenberg, S. D. Collins, Q. Sheng, J. Wallweber, L. Defazio-Eli, C. L. Arteaga, Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110a inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Cancer Res. 10.1158/0008-5472.CAN-13-1191 (2013).
    • (2013) Cancer Res.
    • Garrett, J.T.1    Sutton, C.R.2    Kurupi, R.3    Bialucha, C.U.4    Ettenberg, S.A.5    Collins, S.D.6    Sheng, Q.7    Wallweber, J.8    Defazio-Eli, L.9    Arteaga, C.L.10
  • 61
    • 79957839340 scopus 로고    scopus 로고
    • Adaptive informatics for multifactorial and high-content biological data
    • B. L. Millard, M. Niepel, M. P. Menden, J. L. Muhlich, P. K. Sorger, Adaptive informatics for multifactorial and high-content biological data. Nat. Methods 8, 487-493 (2011).
    • (2011) Nat. Methods , vol.8 , pp. 487-493
    • Millard, B.L.1    Niepel, M.2    Menden, M.P.3    Muhlich, J.L.4    Sorger, P.K.5
  • 62
    • 0038620211 scopus 로고    scopus 로고
    • Prediction of clinical outcome with microarray data: A partial least squares discriminant analysis (PLS-DA) approach
    • M. Pérez-Enciso, M. Tenenhaus, Prediction of clinical outcome with microarray data: A partial least squares discriminant analysis (PLS-DA) approach. Hum. Genet. 112, 581-592 (2003).
    • (2003) Hum. Genet. , vol.112 , pp. 581-592
    • Pérez-Enciso, M.1    Tenenhaus, M.2
  • 63
    • 84885810103 scopus 로고    scopus 로고
    • Morgan Kaufmann Publishers, Burlington, MA, ed. 3, chap. 5.3
    • I. H. Witten, E. Frank, M. A. Hall, Data Mining (Morgan Kaufmann Publishers, Burlington, MA, ed. 3, 2011), chap. 5.3.
    • (2011) Data Mining
    • Witten, I.H.1    Frank, E.2    Hall, M.A.3
  • 64
    • 33644860703 scopus 로고    scopus 로고
    • Bias in error estimation when using cross-validation for model selection
    • A. Varma, R. Simon, Bias in error estimation when using cross-validation for model selection. BMC Bioinformatics 7, 91 (2006).
    • (2006) BMC Bioinformatics , vol.7 , pp. 91
    • Varma, A.1    Simon, R.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.